FDA rejects closely watched lung cancer drug
The FDA has rejected Summit Therapeutics’ application for ivonescimab for certain patients with advanced lung cancer after the treatment did not show a statistically significant improvement in overall survival. Summit said the FDA cited the finding in rejecting the drug, according to a Nov. 15 news release. The application sought approval of ivonescimab with platinum-containing […] The post FDA rejects closely watched lung cancer drug appeared first on Becker's Hospital Review | Healt...
Original Source
Read the full article at Beckershospitalreview →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.